SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.94
+0.07 (+3.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.87
Open1.87
Bid1.40 x 1800
Ask1.95 x 1000
Day's Range1.81 - 1.94
52 Week Range1.48 - 4.09
Volume1,678,962
Avg. Volume510,332
Market Cap144.228M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.74
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.76
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"

    VANCOUVER, Oct. 4, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host a Key Opinion Leader call on the topic of "Unmet Medical Needs in Myelofibrosis" on Wednesday, October 17 at 10:30 am Eastern Time. The call will feature a presentation by distinguished medical oncologist Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas. "Anemia remains one of the most detrimental inadequately addressed aspects of myelofibrosis.

  • CNW Group14 days ago

    Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"

    VANCOUVER , Oct. 4, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host a Key Opinion Leader call on the topic of "Unmet Medical Needs in Myelofibrosis" on Wednesday, October 17 at 10:30 am Eastern Time . The call will feature a presentation by distinguished medical oncologist Dr. Srdan Verstovsek, MD, PhD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas . "Anemia remains one of the most detrimental inadequately addressed aspects of myelofibrosis.

  • Sierra Oncology (SRRA): Moving Average Crossover Alert
    Zacks2 months ago

    Sierra Oncology (SRRA): Moving Average Crossover Alert

    Sierra Oncology, Inc. (SRRA) could be a stock to avoid from a technical perspective

  • PR Newswire2 months ago

    Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib

    VANCOUVER, Aug. 22, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it has obtained a debt facility from Silicon Valley Bank to support the advancement of its drug development programs, including to acquire and advance its Phase 3 drug candidate, momelotinib, for the treatment of myelofibrosis. "This credit facility provides us with the option to access minimally dilutive capital rapidly and incrementally as needed to advance momelotinib, while helping to ensure we remain well capitalized to prosecute our robust development program for SRA737 and commence the clinical program for SRA141," said Dr. Nick Glover, President and CEO of Sierra Oncology.

  • CNW Group2 months ago

    Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib

    VANCOUVER , Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it has obtained a debt facility from Silicon Valley Bank to support the advancement of its drug development programs, including to acquire and advance its Phase 3 drug candidate, momelotinib, for the treatment of myelofibrosis. "This credit facility provides us with the option to access minimally dilutive capital rapidly and incrementally as needed to advance momelotinib, while helping to ensure we remain well capitalized to prosecute our robust development program for SRA737 and commence the clinical program for SRA141," said Dr. Nick Glover , President and CEO of Sierra Oncology.

  • CNW Group2 months ago

    Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

    VANCOUVER , Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced it has acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a potentially differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive spleen and constitutional symptom control.

  • PR Newswire2 months ago

    Sierra Oncology Reports Second Quarter Results

    - SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized ...

  • CNW Group2 months ago

    Sierra Oncology Reports Second Quarter Results

    Sierra Oncology Reports Second Quarter Results

  • CNW Group2 months ago

    Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

    VANCOUVER , Aug. 7, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover , President and Chief Executive Officer, will present an overview of the company at the 2018 Wedbush PacGrow Healthcare Conference being held in New York on August 14-15 . A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DDR therapeutics for the treatment of patients with cancer.

  • PR Newswire2 months ago

    Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

    VANCOUVER, Aug. 7, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company at the 2018 Wedbush PacGrow Healthcare Conference being held in New York on August 14-15. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DDR therapeutics for the treatment of patients with cancer.

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.

  • Can The Uptrend Continue for Sierra Oncology (SRRA)?
    Zacks5 months ago

    Can The Uptrend Continue for Sierra Oncology (SRRA)?

    Investors certainly have to be happy with Sierra Oncology, Inc. (SRRA) and its short term performance

  • ACCESSWIRE5 months ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Associated Press5 months ago

    Sierra Oncology, Inc: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 19 cents. The company's shares closed at $1.97. A year ago, they were trading at $1.25. _____ This story was generated ...

  • CNW Group5 months ago

    Sierra Oncology Reports First Quarter Results

    Sierra Oncology Reports First Quarter Results

  • CNW Group6 months ago

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

  • CNW Group7 months ago

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

  • PR Newswire7 months ago

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    VANCOUVER, March 19, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Angie You, Chief Business & Strategy Officer, Head of Commercial, will present an overview of the company at the Future Leaders in the Biotech Industry Conference being held in New York. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DDR therapeutics for the treatment of patients with cancer.

  • PR Newswire7 months ago

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    VANCOUVER , March 14, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for ...

  • CNW Group7 months ago

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

  • PR Newswire8 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    VANCOUVER, March 2, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,000,000 shares of its common stock at a price of $2.25 per share, with expected gross proceeds to Sierra Oncology of $42,750,000. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,850,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Sierra Oncology intends to use the net proceeds from the public offering to fund development of its product candidates, SRA737 and SRA141, as well as for general corporate purposes.

  • CNW Group8 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    Sierra Oncology Announces Pricing of Public Offering of Common Stock